Akebia Therapeutics Analyst Ratings
Akebia Therapeutics Analyst Ratings
While ratings are subjective and will change, the latest Akebia Therapeutics (AKBA) rating was a maintained with a price target of $3.75 to $5.00. The current price Akebia Therapeutics (AKBA) is trading at is $1.05, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/17/2023 | 376.19% | HC Wainwright & Co. | $3.75 → $5 | Maintains | Buy |
| 09/27/2023 | 257.14% | HC Wainwright & Co. | → $3.75 | Reiterates | Buy → Buy |
| 08/28/2023 | 257.14% | HC Wainwright & Co. | $2 → $3.75 | Upgrades | Neutral → Buy |
| 08/11/2023 | 90.48% | HC Wainwright & Co. | → $2 | Reiterates | Neutral → Neutral |
| 06/21/2023 | 90.48% | HC Wainwright & Co. | → $2 | Reiterates | Neutral → Neutral |
| 06/14/2023 | 90.48% | HC Wainwright & Co. | → $2 | Reiterates | Neutral → Neutral |
| 06/02/2023 | 90.48% | HC Wainwright & Co. | → $2 | Reiterates | Neutral → Neutral |
| 05/31/2023 | 280.95% | Piper Sandler | $2 → $4 | Upgrades | Neutral → Overweight |
| 05/30/2023 | 90.48% | HC Wainwright & Co. | → $2 | Reiterates | Neutral → Neutral |
| 05/26/2023 | 90.48% | HC Wainwright & Co. | → $2 | Reiterates | Neutral → Neutral |
| 05/09/2023 | 90.48% | Needham | → $2 | Reiterates | → Neutral |
| 04/26/2023 | 90.48% | HC Wainwright & Co. | $1.25 → $2 | Maintains | Neutral |
| 03/31/2023 | 19.05% | HC Wainwright & Co. | → $1.25 | Reiterates | → Neutral |
| 03/10/2023 | 19.05% | HC Wainwright & Co. | → $1.25 | Reiterates | → Neutral |
| 02/22/2023 | 19.05% | HC Wainwright & Co. | → $1.25 | Maintains | Neutral |
| 05/16/2022 | 19.05% | HC Wainwright & Co. | $2 → $1.25 | Maintains | Neutral |
| 03/31/2022 | 90.48% | HC Wainwright & Co. | $10 → $2 | Downgrades | Buy → Neutral |
| 03/31/2022 | — | Needham | Downgrades | Buy → Hold | |
| 03/31/2022 | 90.48% | Mizuho | $6 → $2 | Downgrades | Buy → Neutral |
| 03/31/2022 | 90.48% | Piper Sandler | $8 → $2 | Downgrades | Overweight → Neutral |
| 11/11/2021 | 852.38% | HC Wainwright & Co. | $6 → $10 | Maintains | Buy |
| 03/08/2021 | 661.9% | Cantor Fitzgerald | → $8 | Initiates Coverage On | → Overweight |
| 03/08/2021 | 471.43% | HC Wainwright & Co. | $9 → $6 | Maintains | Buy |
| 01/29/2021 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 10/26/2020 | 757.14% | HC Wainwright & Co. | $10 → $9 | Maintains | Buy |
| 09/04/2020 | 185.71% | Morgan Stanley | $12 → $3 | Maintains | Equal-Weight |
| 09/04/2020 | 471.43% | BTIG | $26 → $6 | Maintains | Buy |
| 09/04/2020 | 852.38% | HC Wainwright & Co. | $17 → $10 | Maintains | Buy |
| 07/15/2020 | 1042.86% | Morgan Stanley | $11 → $12 | Maintains | Equal-Weight |
| 05/06/2020 | 1614.29% | JP Morgan | $13 → $18 | Maintains | Overweight |
| 05/06/2020 | 947.62% | Morgan Stanley | $9 → $11 | Maintains | Equal-Weight |
| 05/06/2020 | 1519.05% | HC Wainwright & Co. | $16 → $17 | Maintains | Buy |
| 05/06/2020 | 1519.05% | Mizuho | $15 → $17 | Maintains | Buy |
| 05/05/2020 | 1614.29% | Needham | $15 → $18 | Maintains | Buy |
| 03/11/2020 | 1328.57% | Mizuho | $16 → $15 | Reiterates | → Buy |
| 02/20/2020 | 1138.1% | JP Morgan | $10 → $13 | Maintains | Overweight |
| 11/18/2019 | 1423.81% | HC Wainwright & Co. | $17 → $16 | Maintains | Buy |
| 08/06/2019 | 1519.05% | HC Wainwright & Co. | $19 → $17 | Maintains | Buy |
| 05/02/2019 | — | JP Morgan | Initiates Coverage On | → Overweight | |
| 03/20/2019 | 757.14% | Citigroup | → $9 | Initiates Coverage On | → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/17/2023 | 376.19% | HC Wainwright & Co. | 3.75 美元 → 5 美元 | 維護 | 買 |
| 09/27/2023 | 257.14% | HC Wainwright & Co. | → 3.75 美元 | 重申 | 購買 → 購買 |
| 08/28/2023 | 257.14% | HC Wainwright & Co. | $2 → 3.75 美元 | 升級 | 中性 → 買入 |
| 08/11/2023 | 90.48% | HC Wainwright & Co. | → 2 美元 | 重申 | 中性 → 中性 |
| 06/21/2023 | 90.48% | HC Wainwright & Co. | → 2 美元 | 重申 | 中性 → 中性 |
| 06/14/2023 | 90.48% | HC Wainwright & Co. | → 2 美元 | 重申 | 中性 → 中性 |
| 06/02/2023 | 90.48% | HC Wainwright & Co. | → 2 美元 | 重申 | 中性 → 中性 |
| 05/31/2023 | 280.95% | 派珀·桑德勒 | 2 美元 → 4 美元 | 升級 | 中性 → 超重 |
| 05/30/2023 | 90.48% | HC Wainwright & Co. | → 2 美元 | 重申 | 中性 → 中性 |
| 05/26/2023 | 90.48% | HC Wainwright & Co. | → 2 美元 | 重申 | 中性 → 中性 |
| 05/09/2023 | 90.48% | 尼德姆 | → 2 美元 | 重申 | → 中立 |
| 2023 年 4 月 26 日 | 90.48% | HC Wainwright & Co. | 1.25 美元 → 2 美元 | 維護 | 中立 |
| 03/31/2023 | 19.05% | HC Wainwright & Co. | → 1.25 美元 | 重申 | → 中立 |
| 03/10/2023 | 19.05% | HC Wainwright & Co. | → 1.25 美元 | 重申 | → 中立 |
| 02/22/2023 | 19.05% | HC Wainwright & Co. | → 1.25 美元 | 維護 | 中立 |
| 05/16/2022 | 19.05% | HC Wainwright & Co. | 2 美元 → 1.25 美元 | 維護 | 中立 |
| 03/31/2022 | 90.48% | HC Wainwright & Co. | 10 美元 → 2 美元 | 降級 | 買入 → 中性 |
| 03/31/2022 | — | 尼德姆 | 降級 | 買入 → 持有 | |
| 03/31/2022 | 90.48% | 瑞穗市 | 6 美元 → 2 美元 | 降級 | 買入 → 中性 |
| 03/31/2022 | 90.48% | 派珀·桑德勒 | 8 美元 → 2 美元 | 降級 | 超重 → 中性 |
| 11/11/2021 | 852.38% | HC Wainwright & Co. | 6 美元 → 10 美元 | 維護 | 買 |
| 2021 年 8 月 3 日 | 661.9% | 坎託·菲茨傑拉德 | → 8 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 2021 年 8 月 3 日 | 471.43% | HC Wainwright & Co. | 9 美元 → 6 美元 | 維護 | 買 |
| 2021 年 1 月 29 日 | — | 摩根大通 | 降級 | 中性 → 體重不足 | |
| 10/26/2020 | 757.14% | HC Wainwright & Co. | 10 美元 → 9 美元 | 維護 | 買 |
| 2020 年 4 月 9 日 | 185.71% | 摩根士丹利 | 12 美元 → 3 美元 | 維護 | 重量相等 |
| 2020 年 4 月 9 日 | 471.43% | BTIG | 26 美元 → 6 美元 | 維護 | 買 |
| 2020 年 4 月 9 日 | 852.38% | HC Wainwright & Co. | 17 美元 → 10 美元 | 維護 | 買 |
| 07/15/2020 | 1042.86% | 摩根士丹利 | 11 美元 → 12 美元 | 維護 | 重量相等 |
| 2020 年 6 月 5 日 | 1614.29% | 摩根大通 | 13 美元 → 18 美元 | 維護 | 超重 |
| 2020 年 6 月 5 日 | 947.62% | 摩根士丹利 | 9 美元 → 11 美元 | 維護 | 重量相等 |
| 2020 年 6 月 5 日 | 1519.05% | HC Wainwright & Co. | 16 美元 → 17 美元 | 維護 | 買 |
| 2020 年 6 月 5 日 | 1519.05% | 瑞穗市 | 15 美元 → 17 美元 | 維護 | 買 |
| 05/05/2020 | 1614.29% | 尼德姆 | 15 美元 → 18 美元 | 維護 | 買 |
| 03/11/2020 | 1328.57% | 瑞穗市 | 16 美元 → 15 美元 | 重申 | → 購買 |
| 02/20/2020 | 1138.1% | 摩根大通 | 10 美元 → 13 美元 | 維護 | 超重 |
| 11/18/2019 | 1423.81% | HC Wainwright & Co. | 17 美元 → 16 美元 | 維護 | 買 |
| 08/06/2019 | 1519.05% | HC Wainwright & Co. | 19 美元 → 17 美元 | 維護 | 買 |
| 2019 年 2 月 5 日 | — | 摩根大通 | 啓動覆蓋範圍開啓 | → 超重 | |
| 2019 年 3 月 20 日 | 757.14% | 花旗集團 | → 9 美元 | 啓動覆蓋範圍開啓 | → 中立 |
What is the target price for Akebia Therapeutics (AKBA)?
Akebia Therapeutics（AKBA）的目標價格是多少？
The latest price target for Akebia Therapeutics (NASDAQ: AKBA) was reported by HC Wainwright & Co. on November 17, 2023. The analyst firm set a price target for $5.00 expecting AKBA to rise to within 12 months (a possible 376.19% upside). 15 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年11月17日公佈了Akebia Therapeutics（納斯達克股票代碼：AKBA）的最新目標股價。該分析公司將目標股價定爲5.00美元，預計AKBA將在12個月內升至12個月內（可能上漲376.19％）。去年有15家分析公司公佈了評級。
What is the most recent analyst rating for Akebia Therapeutics (AKBA)?
分析師對Akebia Therapeutics（AKBA）的最新評級是多少？
The latest analyst rating for Akebia Therapeutics (NASDAQ: AKBA) was provided by HC Wainwright & Co., and Akebia Therapeutics maintained their buy rating.
HC Wainwright & Co. 提供了Akebia Therapeutics（納斯達克股票代碼：AKBA）的最新分析師評級，Akebia Therapeutics維持買入評級。
When is the next analyst rating going to be posted or updated for Akebia Therapeutics (AKBA)?
Akebia Therapeutics（AKBA）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Akebia Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Akebia Therapeutics was filed on November 17, 2023 so you should expect the next rating to be made available sometime around November 17, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Akebia Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Akebia Therapeutics的最新評級是在2023年11月17日公佈的，因此您應該預計下一個評級將在2024年11月17日左右公佈。
Is the Analyst Rating Akebia Therapeutics (AKBA) correct?
分析師對Akebia Therapeutics（AKBA）的評級正確嗎？
While ratings are subjective and will change, the latest Akebia Therapeutics (AKBA) rating was a maintained with a price target of $3.75 to $5.00. The current price Akebia Therapeutics (AKBA) is trading at is $1.05, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Akebia Therapeutics（AKBA）評級維持不變，目標股價爲3.75美元至5.00美元。Akebia Therapeutics（AKBA）目前的交易價格爲1.05美元，超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。